| Literature DB >> 31698710 |
Vanessa Rosse de Souza1, Mariana Concentino Menezes Brum2, Isabella Dos Santos Guimarães3, Paula de Freitas Dos Santos2, Thuane Oliveira do Amaral1, Joel Pimentel Abreu1, Thuane Passos1, Otniel Freitas-Silva4, Etel Rodrigues Pereira Gimba2,5, Anderson Junger Teodoro1.
Abstract
Murici (Byrsonima crassifolia (L.) Kunth and B. verbascifolia (L.) DC.) and tapereba (Spondias mombin) are Amazonian fruits that contain bioactive compounds. Biochemical and molecular characterization of these fruits can reveal their potential use in preventing diseases, including cancer. The extracts were characterized regarding the presence and profile of carotenoids by high-performance liquid chromatography (HPLC), total phenolic content by the Folin-Ciocalteu assay, and antioxidant activity by antioxidant value 2,2-diphenyl-1-picrylhydrazyl (DPPH) content analysis, 22,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) content analysis, Ferric-Reducing Ability of Plasma (FRAP), and Oxygen Radical Absorbance Capacity (ORAC) analysis. The extracts of tapereba and murici studied were important sources of total carotenoids and lutein, respectively. The extracts were then tested for their effect on the viability of the A2780 ovarian cancer (OC) cell line and its cisplatin (CDDP)-resistant derived cell line, called ACRP, by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. Their influence on cell cycle and apoptosis were analyzed by using flow cytometry. Murici and tapereba cell extracts exhibited a strong bioactivity by inhibiting A2780 and ACRP cell viability by 76.37% and 78.37%, respectively, besides modulating the cell cycle and inducing apoptotic cell death. Our results open new perspectives for the development of innovative therapeutic strategies using these Amazon fruit extracts to sensitize ovarian cancer cells to current chemotherapeutic options.Entities:
Keywords: Byrsonima crassifolia; Byrsonima verbascifolia; Spondias mombin; carotenoids; cisplatin; ovarian cancer
Year: 2019 PMID: 31698710 PMCID: PMC6921045 DOI: 10.3390/biom9110707
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Total phenolic content and antioxidant potential of ME and TAP evaluated by different assays.
| Parameter | ME | TAP |
|---|---|---|
| Total phenolics (mg gallic acid (GAE)/mL) | 1634.05 ± 278.18 a | 1049.09 ± 95.68 b |
| ORAC assay (μM TE/g) | 1020.39 ± 88.43 a | 623.72 ± 38.75 b |
| FRAP assay (μmol ferrous sulphate/g) | 1014.71 ± 2.08 a | 644.55 ± 10.89 b |
| DPPH assay (% reduction) | 70.17 ± 4.61 a | 78.70 ± 0.28 b |
| TEAC assay (μmol TE/g) | 1620.95 ± 114.65 a | 1090.90 ± 296.04 b |
Results expressed as mean ± standard deviation. Different letters (a,b) in the same row indicate significant difference (p < 0.05). ME = murici extract; TAP = tapereba extract; TE = Trolox equivalent; GAE = gallic acid equivalent.
Carotenoid content of pulp extracts of murici and tapereba (µg/g).
| Parameter | ME | TAP |
|---|---|---|
| Total carotenoids | 86.30 ± 8.82 b | 185.92 ± 12.86 a |
| Lutein | 23.39 ± 1.41 a | 11.96 ± 0.07 b |
| Zeaxanthin | 5.20 ± 1.02 a | 1.25 ± 0.10 b |
| Zeinoxanthin | 1.92 ± 0.21 b | 45.72 ± 2.92 a |
| β-cryptoxanthin | 1.32 ± 0.34 b | 89.81 ± 4.58 a |
| α-carotene | 0.48 ± 0.11 b | 18.25 ± 2.99 a |
| β-carotene | 4.61 ± 1.62 b | 17.45 ± 3.57 a |
Results expressed in mean ± standard deviation. Different letters (a,b) in the same row indicate significant difference (p < 0.05). ME = murici extract and TAP = tapereba extract.
Figure 1Effect of ME and TAP on A2780 cell viability. ME (A) and TAP (B) were tested for their effect on A2780 cell viability after 24 h of treatment using MTT assays. Significant differences between the untreated cells and those incubated with the respective extracts (0.01–20 mg/mL) were compared by one-way ANOVA, followed by Tukey’s post-test (* p < 0.05; ** p < 0.01). Bar 100 µm.
Figure 2Effect of ME and TAP on ACRP cell viability. ME (A) and TAP (B) were tested for their effect on ACRP cell viability after 24 h of treatment using MTT assays. Significant differences between the untreated cells and those incubated with the respective extracts (0.01–20.0 mg/mL) were compared by one-way ANOVA followed by Tukey’s post-test (* p < 0.05; ** p < 0.01). Bar 100 µm.
Figure 3ME and TAP inhibit A2780 and ACRP cell cycle progression. A2780 and ACRP cells were tested for cell cycle progression in response to 24 h treatment with ME and TAP extracts (A). Flow cytometric analysis results are shown after treatment for 24 h with both cell extracts (5 mg/mL) and bar graphs represent the percentage of A2780 (B) or ACRP (C) cells in each cell cycle phase. The results are expressed as % of cells in sub-G0, G0/G1, S, and G2/M phases after cell treatment with ME or TAP.
Figure 4Effect of murici (ME) and tapereba (TAP) extracts on apoptotic rates in A2780 and ACRP cell lines. A2780 (top panel) and ACRP (bottom panel) cell lines were treated with ME or TAP for 24 h at 5 and 20 mg/mL. The table at the bottom part of this figure shows the apoptotic rates as described in the Material and Methods section. Different letters (a,b,c) in the same row indicate statistically significant differences (p < 0.05).
Figure 5Effect of ME and TAP on CDDP of A2780 and ACRP cell viability. Effect of ME (A,C) and TAP (B,D) at the concentrations of 5 (ME5 or TAP5) and 20 mg/mL (ME20 or TAP20) on cell viability of A2780 (A,B) or ACRP (C,D) after 24 h of isolated or combined treatment with CDDP at 10 µM for A2780 (CDDP10) or 80 µM for ACRP (CDDP80) using MTT assays. The results are expressed as mean ± standard deviation of three independent experiments. Significant differences between the untreated cells (CT) and those incubated with the respective extracts were compared by one-way ANOVA followed by the Tukey’s post-test (* p < 0.05; ** p < 0.01; *** p < 0.001).